Hepatitis C: CIFN for re-treatment of PEG-IFN plus RBV nonresponders?
Trepo
Christian
C
Department of Hepatogastroenterology Hôtel Dieu Hospital University, Claude Bernard Lyon 1, and Hepatitis INSERM Unit U871, Lyon, France. christian.trepo@chu-lyon.fr
Pradat
Pierre
P
D000998:Antiviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C050739:interferon alfacon-1; C100416:peginterferon alfa-2a